Archeon Medical raises $9m Series A for ventilation monitoring
HEKA leads funding for US clinical studies and commercial expansion of the EOlife feedback system.
Archeon Medical announced $9 million in Series A equity financing on 6 October 2026. HEKA, managed by Newfund, led the round, joined by Eiffel Investment Group, the OSER BFC fund managed by UI Investissement, Majycc Innovation Santé and Karot Capital.
The Besançon company develops EOlife, a device that measures air delivered during manual ventilation and gives emergency responders real-time visual feedback. It serves both clinical and training settings.
Proceeds will support US clinical validation and commercial scale-up. Archeon is pursuing studies involving more than 1,500 cardiac arrest patients across European and US sites to assess the device in real-world emergency care.